Cefuroxime

Overview

Cefuroxime (Ceftin®, Zinacef®) is a semisynthetic second-generation cephalosporin antibiotic available in both oral (cefuroxime axetil) and injectable (cefuroxime sodium) formulations. Compared with first-generation cephalosporins, cefuroxime provides enhanced activity against certain gram-negative bacteria while maintaining activity against many gram-positive organisms.

In veterinary medicine, cefuroxime has limited clinical experience in dogs and cats but may be considered when a cephalosporin is desired and resistance to first-generation agents is suspected, or when slightly broader gram-negative coverage is needed. It may also be used for surgical prophylaxis or in infections involving the central nervous system when inflamed meninges allow penetration into cerebrospinal fluid.

Mechanism of Action (MOA): Cefuroxime acts as a time-dependent bactericidal antibiotic by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins involved in the final stage of peptidoglycan formation, disrupting cell wall integrity and leading to bacterial cell lysis. Its antimicrobial spectrum includes many gram-positive and gram-negative organisms such as Escherichia coli, Klebsiella pneumoniae, Salmonella spp., and Enterobacter spp., but it is ineffective against methicillin-resistant staphylococci, Pseudomonas spp., Serratia spp., enterococci, and extended-spectrum beta-lactamase–producing bacteria.

Indications

Cefuroxime may be used in dogs and cats for treatment of bacterial infections caused by organisms susceptible to second-generation cephalosporins. Although clinical experience in veterinary medicine is limited, it may be considered when broader gram-negative coverage is desired or when infections are resistant to first-generation cephalosporins.

• Susceptible bacterial infections: Used for treatment of infections caused by organisms sensitive to cefuroxime when other cephalosporins are ineffective or resistance to first-generation agents is suspected.
• Surgical prophylaxis: May be administered prior to surgical procedures to provide antimicrobial coverage, particularly when slightly enhanced gram-negative activity is desired compared with first-generation cephalosporins.
• Central nervous system infections: May be considered for treatment of bacterial meningitis or other CNS infections because cefuroxime can penetrate cerebrospinal fluid when the meninges are inflamed.

Dosage (Reference)

Dog

In dogs, cefuroxime is used extra-label for treatment of infections caused by susceptible bacteria. It may be administered parenterally or orally depending on the formulation used. Dosing intervals are based on pharmacokinetic data and bacterial susceptibility (MIC).

Cat

In cats, cefuroxime is used extra-label for treatment of susceptible bacterial infections. Available dosing recommendations are extrapolated from limited veterinary data and pharmacokinetic studies.

Warnings & Precautions

Clinical experience with cefuroxime in veterinary patients is limited. As with other cephalosporins, patient selection, allergy history, and renal function should be considered before initiating therapy.

• Hypersensitivity reactions: Cefuroxime is contraindicated in patients with known hypersensitivity to cephalosporins. Allergic reactions may occur independent of dose and can range from mild dermatologic reactions to severe anaphylaxis.
• Cross-reactivity with beta-lactam antibiotics: Patients with documented hypersensitivity to penicillins or other beta-lactam antibiotics may also react to cephalosporins. Use cautiously in animals with a history of penicillin allergy.
• Limited veterinary data: Clinical experience with cefuroxime in dogs and cats is limited, and most dosing recommendations are based on pharmacokinetic studies or extrapolation from human medicine.
• Renal function: Cefuroxime is primarily eliminated through the kidneys. Animals with severe renal impairment may require dosage adjustments and closer monitoring during therapy.
• Drug name confusion: Cefuroxime may be confused with other cephalosporins with similar names. Care should be taken when prescribing or dispensing to avoid medication errors.
• Antimicrobial stewardship: Cephalosporins are considered highly important antimicrobials in human medicine; therefore, cefuroxime should be used judiciously and ideally guided by culture and susceptibility testing.

Drug Interactions

Several drug interactions with cefuroxime have been reported or are considered theoretically possible. Most involve altered drug absorption or additive nephrotoxic effects when combined with other medications. Careful monitoring is recommended when cefuroxime is used concurrently with the following agents.

• Aminoglycosides (e.g., gentamicin, amikacin): Concurrent use may increase the risk of nephrotoxicity. However, aminoglycosides and cephalosporins may demonstrate synergistic antibacterial activity against some gram-negative organisms. Renal function should be monitored.
• Nephrotoxic drugs (e.g., amphotericin B, furosemide): Combined use with cefuroxime may increase the risk of additive kidney toxicity. Use cautiously and monitor renal parameters when therapy is combined.
• Antacids containing aluminum, calcium, or magnesium: May decrease the absorption of oral cefuroxime. Separate administration by approximately 1–2 hours to minimize interaction.
• H2-receptor antagonists (e.g., famotidine, ranitidine): These drugs may significantly reduce absorption of oral cefuroxime and concurrent use is generally not recommended.
• Proton pump inhibitors (e.g., omeprazole, pantoprazole): May decrease the gastrointestinal absorption of cefuroxime, potentially reducing therapeutic concentrations.
• Sodium bicarbonate: May reduce absorption of oral cefuroxime when administered concurrently. Doses should be separated by 1–2 hours.
• Probenecid: Inhibits renal tubular secretion of cephalosporins, which may increase serum concentrations and prolong the half-life of cefuroxime.
• Vitamin K antagonists: Cephalosporins may enhance the anticoagulant effects of vitamin K antagonists, increasing the risk of bleeding in susceptible patients.

Side Effects & Overdose

Side Effects

Because clinical experience with cefuroxime in dogs and cats is limited, a complete adverse effect profile has not been fully established. However, based on available veterinary reports and known effects of cephalosporin antibiotics, gastrointestinal disturbances are the most commonly expected adverse reactions.

• Gastrointestinal effects: Inappetence, vomiting, and diarrhea are the most commonly reported adverse effects in small animals receiving cefuroxime.
• Hypersensitivity reactions: Allergic reactions may occur in animals sensitive to cephalosporins or other beta-lactam antibiotics. These reactions may include rash, pruritus, fever, or rarely anaphylaxis.
• Injection site reactions: Local irritation or inflammation may occur when cefuroxime is administered intravenously or intramuscularly.
• Hematologic changes: Prolonged or very high dosing in experimental studies has been associated with mild decreases in neutrophils or red blood cells and prolonged clotting times.
• Neurologic reactions (rare): Cephalosporins may rarely cause neurologic effects such as seizures, particularly in patients receiving very high doses or those with impaired renal function.

Overdose

Cefuroxime appears to have a relatively wide safety margin. Toxicity is unlikely with moderate overdose, but very large doses may produce neurologic or gastrointestinal complications.

• Gastrointestinal upset: Vomiting, diarrhea, and reduced appetite may occur following excessive dosing.
• Neurologic toxicity: Large overdoses may cause central nervous system irritation and seizures.
• Hematologic effects: Extremely high doses over prolonged periods may contribute to abnormalities in blood cell counts or clotting parameters.
• Management: Treatment of overdose is primarily supportive, including discontinuation of the drug, monitoring of renal function, and management of clinical signs.
• Drug removal: Plasma concentrations may be reduced through dialysis techniques in severe overdose situations.

Key Notes

Practical clinical points that may assist veterinarians when considering cefuroxime therapy in dogs and cats:

• Alternative cephalosporin option: Cefuroxime may be considered when infections show reduced susceptibility to first-generation cephalosporins but a cephalosporin-class drug is still preferred.
• Enhanced gram-negative coverage: Compared with first-generation cephalosporins, cefuroxime provides somewhat improved activity against certain gram-negative organisms.
• CNS penetration: Therapeutic concentrations may be achieved in cerebrospinal fluid when the meninges are inflamed, making cefuroxime a potential option for bacterial CNS infections.
• Limited veterinary clinical experience: Most available information in dogs and cats is derived from pharmacokinetic studies rather than large clinical trials.
• Formulation differences: Cefuroxime is available as both an oral prodrug (cefuroxime axetil) and an injectable salt (cefuroxime sodium), which differ in absorption and route of administration.
• Antimicrobial classification: Cefuroxime is considered a highly important antimicrobial in human medicine, so responsible and judicious veterinary use is recommended.